Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 59

1.

Immunohistochemical Profile of Breast Cancer With Respect to Estrogen Receptor and HER2 Status.

Gloyeske NC, Woodard AH, Elishaev E, Yu J, Clark BZ, Dabbs DJ, Bhargava R.

Appl Immunohistochem Mol Morphol. 2014 Oct 29. [Epub ahead of print]

PMID:
25356941
[PubMed - as supplied by publisher]
2.

A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages.

Lu H, Clauser KR, Tam WL, Fröse J, Ye X, Eaton EN, Reinhardt F, Donnenberg VS, Bhargava R, Carr SA, Weinberg RA.

Nat Cell Biol. 2014 Nov;16(11):1105-17. doi: 10.1038/ncb3041. Epub 2014 Sep 28.

PMID:
25266422
[PubMed - in process]
3.

Clinical utility of immunohistochemistry and other ancillary techniques in assessment of uterine tumors.

Bhargava R.

Semin Diagn Pathol. 2014 May;31(3):193-4. doi: 10.1053/j.semdp.2014.03.001. Epub 2014 Apr 1. No abstract available.

PMID:
24933036
[PubMed - indexed for MEDLINE]
4.

Semiquantitative GATA-3 immunoreactivity in breast, bladder, gynecologic tract, and other cytokeratin 7-positive carcinomas.

Clark BZ, Beriwal S, Dabbs DJ, Bhargava R.

Am J Clin Pathol. 2014 Jul;142(1):64-71. doi: 10.1309/AJCP8H2VBDSCIOBF.

PMID:
24926087
[PubMed - indexed for MEDLINE]
5.

Interpretation of human epidermal growth factor receptor 2 (HER2) in situ hybridization assays using 2013 update of American Society of Clinical Oncology/College of American Pathologists HER2 Guidelines.

Bhargava R, Dabbs DJ.

J Clin Oncol. 2014 Jun 10;32(17):1855. doi: 10.1200/JCO.2013.53.9213. Epub 2014 Apr 28. No abstract available.

PMID:
24778404
[PubMed - indexed for MEDLINE]
6.

Low ER+ breast cancer: Is this a distinct group?

Gloyeske NC, Dabbs DJ, Bhargava R.

Am J Clin Pathol. 2014 May;141(5):697-701. doi: 10.1309/AJCP34CYSATWFDPQ.

PMID:
24713741
[PubMed - indexed for MEDLINE]
7.

Bright-field HER2 dual in situ hybridization (DISH) assay vs fluorescence in situ hybridization (FISH): focused study of immunohistochemical 2+ cases.

Gao FF, Dabbs DJ, Cooper KL, Bhargava R.

Am J Clin Pathol. 2014 Jan;141(1):102-10. doi: 10.1309/AJCP6CXS8OSRHXIR.

PMID:
24343743
[PubMed - indexed for MEDLINE]
8.

Metabolic alterations in mammary cancer prevention by withaferin A in a clinically relevant mouse model.

Hahm ER, Lee J, Kim SH, Sehrawat A, Arlotti JA, Shiva SS, Bhargava R, Singh SV.

J Natl Cancer Inst. 2013 Aug 7;105(15):1111-22. doi: 10.1093/jnci/djt153. Epub 2013 Jul 2.

PMID:
23821767
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Profilin-1 downregulation has contrasting effects on early vs late steps of breast cancer metastasis.

Ding Z, Joy M, Bhargava R, Gunsaulus M, Lakshman N, Miron-Mendoza M, Petroll M, Condeelis J, Wells A, Roy P.

Oncogene. 2014 Apr 17;33(16):2065-74. doi: 10.1038/onc.2013.166. Epub 2013 May 20.

PMID:
23686314
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Clinicopathologic study of serous tubal intraepithelial carcinoma with invasive carcinoma: is serous tubal intraepithelial carcinoma a reliable feature for determining the organ of origin?

Gao FF, Bhargava R, Yang H, Li Z, Zhao C.

Hum Pathol. 2013 Aug;44(8):1534-43. doi: 10.1016/j.humpath.2012.12.007. Epub 2013 Mar 1.

PMID:
23465279
[PubMed - indexed for MEDLINE]
11.

Immunohistochemistry and HPV in situ hybridization in pathologic distinction between endocervical and endometrial adenocarcinoma: a comparative tissue microarray study of 76 tumors.

Jones MW, Onisko A, Dabbs DJ, Elishaev E, Chiosea S, Bhargava R.

Int J Gynecol Cancer. 2013 Feb;23(2):380-4. doi: 10.1097/IGC.0b013e31825cc8ee.

PMID:
23318908
[PubMed - indexed for MEDLINE]
12.

Morphologic features do not influence response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer.

Li X, Kanbour-Shakir A, Dabbs DJ, Bhargava R.

Appl Immunohistochem Mol Morphol. 2013 Oct;21(5):420-5. doi: 10.1097/PAI.0b013e318273c1cc.

PMID:
23165332
[PubMed - indexed for MEDLINE]
13.

Interobserver agreement among pathologists for semiquantitative hormone receptor scoring in breast carcinoma.

Cohen DA, Dabbs DJ, Cooper KL, Amin M, Jones TE, Jones MW, Chivukula M, Trucco GA, Bhargava R.

Am J Clin Pathol. 2012 Dec;138(6):796-802. doi: 10.1309/AJCP6DKRND5CKVDD.

PMID:
23161712
[PubMed - indexed for MEDLINE]
Free Article
14.

Impact of progesterone receptor semiquantitative immunohistochemical result on Oncotype DX recurrence score: a quality assurance study of 1074 cases.

Clark BZ, Dabbs DJ, Cooper KL, Bhargava R.

Appl Immunohistochem Mol Morphol. 2013 Jul;21(4):287-91. doi: 10.1097/PAI.0b013e31826f80c9.

PMID:
23060300
[PubMed - indexed for MEDLINE]
15.

A validation study of quantum dot multispectral imaging to evaluate hormone receptor status in ductal carcinoma in situ of the breast.

Yu J, Monaco SE, Onisko A, Bhargava R, Dabbs DJ, Cieply KM, Fine JL.

Hum Pathol. 2013 Mar;44(3):394-401. doi: 10.1016/j.humpath.2012.06.002. Epub 2012 Oct 3.

PMID:
23039940
[PubMed - indexed for MEDLINE]
16.

Uterine adenosarcomas: diagnostic use of the proliferation marker Ki-67 as an adjunct to morphologic diagnosis.

Aggarwal N, Bhargava R, Elishaev E.

Int J Gynecol Pathol. 2012 Sep;31(5):447-52. doi: 10.1097/PGP.0b013e318249285b.

PMID:
22833085
[PubMed - indexed for MEDLINE]
17.

Nuclear nano-morphology markers of histologically normal cells detect the "field effect" of breast cancer.

Bista RK, Wang P, Bhargava R, Uttam S, Hartman DJ, Brand RE, Liu Y.

Breast Cancer Res Treat. 2012 Aug;135(1):115-24. doi: 10.1007/s10549-012-2125-2. Epub 2012 Jun 16.

PMID:
22706633
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

The effect of 96-hour formalin fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma.

Yildiz-Aktas IZ, Dabbs DJ, Cooper KL, Chivukula M, McManus K, Bhargava R.

Am J Clin Pathol. 2012 May;137(5):691-8. doi: 10.1309/AJCPQRAG67GJRPMT.

PMID:
22523206
[PubMed - indexed for MEDLINE]
Free Article
19.

The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma.

Yildiz-Aktas IZ, Dabbs DJ, Bhargava R.

Mod Pathol. 2012 Aug;25(8):1098-105. doi: 10.1038/modpathol.2012.59. Epub 2012 Mar 30.

PMID:
22460807
[PubMed - indexed for MEDLINE]
Free Article
20.

Predictors of pathologic complete response after standard neoadjuvant chemotherapy in triple-negative breast carcinoma.

Kraus JA, Beriwal S, Dabbs DJ, Ahrendt GM, McGuire KP, Johnson RR, Badve P, Puhalla SL, Bhargava R.

Appl Immunohistochem Mol Morphol. 2012 Jul;20(4):334-9. doi: 10.1097/PAI.0b013e31823f4663.

PMID:
22417856
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk